Infectious Disease Advisor news story
Doravirine/islatravir (DOR/ISL) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) are associated with similar improvements in self-reported health status and reductions in bothersome symptoms among previously untreated adults with HIV-1, according to study results presented at IDWeek 2026, held from October 21 to 24, in Washington, DC.
Researchers assessed patient-reported outcomes with DOR/ISL, a novel 2-drug antiretroviral therapy (ART) regimen, compared with BIC/FTC/TAF in a double-blind phase 3 trial (ClinicalTrials.gov Identifier: NCT05705349). The trial previously demonstrated noninferior virologic efficacy and comparable safety between ART regimens at week 48.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
View all Infectious Disease Advisor reports from IDWeek 2026
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
-
[IDWeek 2026] Contagion Live | Asuptegravir lowers HIV-1 RNA up to 2.36 logs in early monotherapy
-
[IDWeek 2026] Infectious Disease Advisor | Bictegravir/lenacapavir well tolerated in people with HIV and comorbidities
-
LSHTM | Six injections a year instead of 365 pills: Can long-acting HIV treatment change care in Africa?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.